ReviewFrontiers in immunology2026
Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refractory classical Hodgkin lymphoma: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with classical Hodgkin lymphoma (cHL) can achieve long-term survival with frontline combination chemotherapy and radiation therapy, but approximately 10%-30% of patients will develop relapsed/refractory (R/R) disease. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) combined with brentuximab vedotin (BV) maintenance therapy improves patient prognosis. However, the management of relapse after ASCT remains a challenge. This report presents a case of a patient with relapsed cHL after ASCT who was successfully treated with targeted therapy combined with two epigenetic modulators. A 26-year-old male patient was diagnosed with stage IIA cHL and received five-line treatment, including ABVD, GemOx-D, anti-PD-1/PD-L1 monoclonal antibodies, anti-CD47/PD-L1 bispecific antibodies, and BV combined with ICE, ultimately achieving first complete remission (CR). The patient subsequently underwent peripheral blood ASCT and BV maintenance therapy. However, 16 months post transplantation, disease relapse was detected on follow-up PET/CT scan. The patient subsequently received 6 cycles of the Ven-Chi-Dec regimen (venetoclax combined with chidamide and decitabine), achieving complete metabolic remission (CMR) with no significant adverse effects. This case report suggests that the Ven-Chi-Dec regimen may be a potential treatment for patients with R/R cHL after ASCT, although further studies are needed to validate its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.